Skip to main content

Table 1 Baseline characteristics and comparisons with the control groups

From: Safety and effectiveness of high-power thulium laser enucleation of the prostate in patients with glands larger than 80 mL

 

Our study

Pilot study: ThuLEP [15]

Pilot study: TURP [15]

Total

Malignancy

Benign

 

P-value**

 

P-value**

Patients

125

15

110

29

 

30

 

Age, years

71.85 ± 8.89

78.81 ± 7.17

71.07 ± 8.68

76.1 ± 9.4

0.02

72.6 ± 7.4

0.62

PSA level, ng/mL

18.40 ± 37.35

37.03 ± 60.34

16.14 ± 33.26

5.0 ± 5.4

0.49

8.3 ± 7.9

0.47

Anticoagulant agent use

5 (4%)

0

5 (4.45%)

15 (51.7%)

 

6 (20.0%)

 

Estimated prostate volume, mL

106.80 ± 45.77

106.80 ± 70.76

106.40 ± 41.25

57.2 ± 25.1

< 0.01

64.7 ± 32.5

< 0.01

Preoperative Foley placement

49 (39.2%)

5 (100%)

44 (40%)

3 (10.34%)

 

7 (23.33%)

 

Transfusion rate

4 (3.2%)

1 (6.67%)

3 (2.72%)

4 (13.79%)

 

8 (26.67%)

 

Reduction ratio of the PSA level 3 months postoperatively (%)

85.59 ± 14.92

  

39.21 ± 44.95

< 0.0001

70.22 ± 28.86

0.0047

Reduction ratio of the estimated prostate size postoperatively (%)

74.17 ± 11.27

  

47.24 ± 16.20

< 0.0001

49.01 ± 17.79

< 0.0001

  1. PSA, prostate-specific antigen, ThuLEP, thulium laser enucleation of the prostate, TURP, transurethral resection of the prostate
  2. **Compared with the total group using Student’s t-test